Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs KTP-001 (Primary)
- Indications Intervertebral disc displacement
- Focus Adverse reactions
- Sponsors Teijin
- 06 Dec 2018 Status changed from active, no longer recruiting to completed.
- 29 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2018.
- 29 Nov 2016 Status changed from recruiting to active, no longer recruiting.